Decoy Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Decoy Therapeutics Inc. (DCOY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.95 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-06.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2019-03-06
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $1.95, a 30.36% decline from fiscal 2017.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $2.80, a 55.91% decline from fiscal 2016.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $6.35, a 25.73% decline from fiscal 2015.
- Decoy Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $8.55.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 10 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|
| 2018-12-31 | $1.95 10-K · filed 2019-03-06 | |
| 2017-12-31 | $2.80 10-K · filed 2019-03-06 | |
| 2016-12-31 | $6.35 10-K · filed 2019-03-06 | |
| 2015-12-31 | $8.55 10-K · filed 2018-03-07 | |
| 2014-12-31 | $2.20 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |